West African crystalline maculopathy

Archives of Ophthalmology

Volumn 121, Issue 3, 2003, Pages 338-342

  Sarraf, David ^a,b,c   Ceron, Olga ^b   Rasheed, Karim ^b   Drenser, Kimberly A ^a   Casey, Richard ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; COLOR VISION TEST; CRYSTAL; CRYSTALLINE MACULOPATHY; ELECTROPHYSIOLOGY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; NIGERIA; PRIORITY JOURNAL; RETINA EXAMINATION; RETINA FOVEA; RETINA MACULOPATHY; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 0037336372     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.3.338     Document Type: Article

References (54)

1. Albert DM, Bullock JD, Lahav M, Caine R. Flecked retina secondary to oxalate crystals from methoxyflurane anaesthesia. Trans Am Acta Ophthatmol Otolaryngol. 1975;79:817-826.
2. Bullock JD, Albert DM. Flecked retina. Arch Ophthalmol. 1975;93:26-31.
3. Novak MA, Roth AS, Levine MR. Calcium oxalate retinopathy associated with methoxyflurane abuse. Retina. 1988;8:230-236.
4. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. Ophthalmology. 1981;88:89-93.
5. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65:177-179.
6. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer. 1992;69:2961-2964.
7. Vinding T, Nielsen NV. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol. 1983;61:45-50.
8. Griffiths MFP. Tamoxifen retinopathy at low dosage. Am J Ophthalmol. 1987;104:185-186.
9. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Res. 1978;62:315-320.
10. Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994;117:772-775.
11. Chang T, Gonder JR, Ventresca MR. Low-dose tamoxifen retinopathy. Can J Ophthalmol. 1992;27:148-149.
12. Chang TS, Aylward W, Clarkson JG, Gass JDM. Asymmetric canthanxanthin retinopathy. Am J Ophthalmol. 1995;119:801-802.
13. Harnois C, Samson J, Malenfant M, Rousseau A. Canthaxanthin retinopathy. Arch Ophthalmol. 1989;107:538-540.
14. Cortin P, Boudreault G, Rousseau AP, et al. La retinopathie a la canthaxanthine, II. Can J Ophthalmol. 1984;19:215-219.
15. Ibanez HE, Williams DF, Boniuk I. Crystalline retinopathy associated with long-term nitrofurantoin therapy. Arch Ophthalmol. 1994;112:304-305.
16. Atlee WE. Talc and cornstarch emboli in eyes of drug abusers. JAMA. 1972;219:49-51.
17. Friberg TR, Gragoudas ES, Regan CDJ. Talc emboli and macular ischemia in intravenous drug abuse. Arch Ophthalmol. 1979;97:1089-1091.
18. Murphy SB, Jackson B, Peter Pare JA. Talc retinopathy. Can J Ophthalmol. 1978;12:152-156.
19. Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol. 1979;87:334-339.
20. Schatz H, Drake M. Self-injected retinal emboli. Ophthalmology. 1979;86:468-485.
21. Bateman HB, Lang GE, Maumenee IH. Multisystem gentic disorders associated with retinal dystrophies. In: Ryan SJ, ed. Retina. Philadelphia, Pa: Mosby Inc; 1994;467-491.
22. Meredith TA, Wright JD, Gammon A, et al. Ocular involvement in primary hyperoxaluria. Arch Ophthalmol. 1984;102:584-587.
23. Sakamoto T, Maeda K, Sueishi K, et al. Ocular histopathologic findings in a 46-year-old man with primary hyperoxaluria. Arch Ophthalmol. 1991;109:384-387.
24. Small KW, Letson R, Scheinman J. Ocular findings in primary hyperoxaluria. Arch Ophthalmol. 1990;108:89-93.
25. Takki K. Gyrate atrophy of the choroid and retina associated with hyperornithinaemia. Br J Ophthalmol. 1974;58:3-23.
26. Williams HE, Smith H. Primary hyperoxaluria. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Book Co; 1978;182-204.
27. Bernauer W, Daicker B. Bietti's corneal-retinal dystrophy. Retina. 1992;12:18-20.
28. Weinberg DV, Sieving PA, Bingham BA, et al. Bietti crystalline retinopathy and juvenile retinoschisis in a family with a novel RS1 mutation. Arch Ophthalmol. 2001;119:1719-1721.
29. Wilson DJ, Weleber RG, Klein ML, et al. Bietti's crystalline dystrophy. Arch Ophthalmol. 1989;107:213-221.
30. Sanderson PO, Kuwabara T, Stark WJ. Cystinosis. Arch Ophthalmol. 1974;91:270-274.
31. Yamamoto GK, Schulman JD, Schneider JA, Wong VG. Long-term ocular changes in cystinosis. J Pediatr Ophthalmol Strabismus. 1979;16:21-25.
32. Jagell S, Polland W, Sandgren O. Specific changes in the fundus typical for the Sjögren-Larsson syndrome: an ophthalmological stud of 35 patients. Acta Ophthalmol. 1980;58:321-330.
33. Traboulsi EI, Faris BM. Crystalline retinopathy. Ann Ophthalmol. 1987;19:156-158.
34. Grizzard WS, Deutman AF, Nijhuis F, Aan De Kerk A. Crystalline retinopathy. Am J Ophthalmol. 1978;86:81-88.
35. Ahmed I, McDonald HR, Schatz H, et al. Crystalline retinopathy associated with chronic retinal detachment. Arch Ophthalmol. 1998;116:1449-1453.
36. Cogan DG, Kuwabara T, Silbert J, et al. Calcium oxalate and calcium phosphate crystals in detached retinas. Arch Ophthalmol. 1958;60:366-371.
37. Kinyoun JL, Knobloch WH. Idiopathic retinal dialysis. Retina. 1984;4:9-14.
38. Gass JDM, Oyakawa RT. Idiopathic juxtafoveal retinal telangectasis. Arch Ophthalmol. 1982;100:604-605.
39. Moisseiev J, Lewis H, Bartov E, et al. Superficial retinal refractile deposits in juxtafoveal telangiectasis. Am J Ophthalmol. 1990;109:604-605.
40. Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol. 1979;88:1-11.
41. Carr RE, Henkind P, Rothfield N. Ocular toxicity of antimalarial drugs. Am J Ophthalmol. 1968;66:738-744.
42. Berstein HM. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(suppl):25-44.
43. Easterbrook M. Dose relationships in patients with early chloroquine retinopathy. J Rheumatol. 1987;14:472-475.
44. Henkind P, Carr RE, Siegel IM. Early chloroquine retinopathy. Arch Ophthalmol. 1964;71:157-165.
45. Magulike NO, Ihenacho HNC, Ike VO. Chloroquine retinopathy in Nigerian patients with heart block. Eye. 1993;7:591-593.
46. Obikili AG. A type of macular degeneration in adult Nigerians. East Afr Med J. 1990;67:614-621.
47. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1992;33:2773-2780.
48. Ogden TE, Callahan F, Riekhof FT. The electroretinogram after peripheral retinal ablation in diabetic retinopathy. Am J Ophthalmol. 1976;81:397-402.
49. Gregor Z, Joffe L. Senile macular changes in the black African. Br J Ophthalmol. 1978;62:547-550.
50. Nwosu SN. Prevalence and pattern of retinal diseases at the Guinness Eye Hospital, Onitsha, Nigeria. Ophthalmic Epidemiol. 2000;17:41-48.
51. Abiose A. Retinal disease in Nigeria - A preliminary report. Niger Med J. 1978;6:180-183.
52. Agatha M, Breckenridge C, Soyemi EA. Some preliminary observation on the effects of kola nut on the cardiovascular system. Niger Med J. 1978;8:501-505.
53. Morton JF. Widespread tannin intake via stimulants and masticatories, especially guarana, kola nut, betel vine and accessories. Basic Life Sci. 1992;59:739-765.55.
54. Ikegwuonu FI, Aire TA, Ogwuegbu SO. Effects of kola-nut extract administration on the liver, kidney, brain, testis and some serum constituents of the rat. J App Toxicol. 1981;1:292-294.